Europe's vaccine campaign has hit a crisis of confidence. Just as the coronavirus pandemic appears to be setting off a new wave of infections, leading European countries have paused the rollout of the AstraZeneca/Oxford University two-dose vaccine following isolated reports of blood clots. Naturally, any adverse affects must be thoroughly investigated, but this is a race against time, and the virus isn't waiting around. European leaders must get the vaccine train back on track — and fast.
